You are here: Industry Insights > CDI

News List

CDI prevention reaches date with destiny pharmatimes
January 17, 2022
Clinical stage outfit, Destiny Pharma, provides a positive summary of the year ahead
Seres and Nestlé enter up to $525m deal for microbiome therapeutic pharmaceutical-technology
July 05, 2021
Seres Therapeutics has signed an agreement with Nestlé Health Science to co-market the former’s investigational treatment, SER-109, for recurrent Clostridioides difficile infection (CDI) in the US and Canada.
COVID-19 convalescent plasma with greater antibody levels is safe and shows promise worldpharmanews
April 07, 2021
Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels of antibodies, according to a new publication by scientists at ...
Hackensack Meridian CDI, Merck Announce COVID-19 Research Collaboration americanpharmaceuticalreview
July 23, 2020
The Hackensack Meridian Center for Discovery and Innovation (CDI) has announced a research collaboration with Merck to investigate drugs for treating COVID-19.
Hackensack Meridian partners with Merck for Covid-19 research pharmaceutical-technology
July 16, 2020
The Hackensack Meridian Center for Discovery and Innovation (CDI) has entered into a research alliance with Merck to explore drugs for the treatment of Covid-19.
Artugen Therapeutics announces first patient dosed with ART24 pharmaceutical-business-review
March 17, 2020
Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious
High-Risk Antibiotic Use Linked to Hospital-Associated C. Difficile drugs
September 18, 2019
Hospital-level high-risk antibiotic use is associated with the risk for hospital-associated (HA) Clostridioides difficile infection (CDI), according to a study published online in Infection Control & Hospital Epidemiology.
Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI americanpharmaceuticalreview
September 03, 2019
Acurx Pharmaceuticals announced its lead product candidate, ACX-362E, has successfully completed the 68-subject, double-blind, placebo-controlled, multiple-ascending dose Phase 1 clinical trial of ACX-362E in healthy volunteers.
Odds of Developing C. Diff Increased in Older Cancer Patients drugs
August 22, 2019
Older adults with cancer have increased odds of developing Clostridiodes difficile infection (CDI), according to a study published in the September issue of Emerging Infectious Diseases...
Substantial Costs Attributable to Hospital-Acquired C. Difficile drugs
July 30, 2019
Hospital-acquired Clostridioides difficile infection (HA-CDI) is associated with substantial attributable costs...

Previous page 1 2 Next page